文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

立体定向放射外科治疗脑干转移瘤:一项多中心回顾性研究

Stereotactic radiosurgery for the treatment of brainstem metastases: a multicenter retrospective study.
PubMed 文献 · Radiat Oncol · 2022-08-09

这项多中心回顾性研究评估了105例患者共111个脑干转移瘤接受直线加速器立体定向放射外科或大分割立体定向放疗的疗效与毒性,1年无局部进展率为90.4%,中位总生存11个月、癌症特异性生存14.6个月,同步靶向治疗与更长总生存显著相关,治疗相关毒性低。

要点

  • 1年无局部进展率为90.4%,中位总生存11个月,中位癌症特异性生存14.6个月。
  • 多因素分析中同步靶向治疗与更长总生存显著相关[HR 0.514(95%CI 0.302-0.875);p=0.01]。
  • 神经系统死亡发生于30.4%的患者,但仅3例(2.8%)归因于局部进展。

核心结论

  • 基于直线加速器的立体定向放射外科/大分割立体定向放疗为脑干转移瘤患者提供了良好的局部控制,治疗相关毒性低,且对总生存无 apparent 不利影响。
  • 以消融意图治疗时,脑干转移瘤是神经系统死亡的少见原因。
  • 作者认为脑干转移瘤患者不应被先验地排除在临床试验之外。

研究设计与样本

  • 多中心回顾性研究,纳入2008年至2021年间在不同临床中心接受立体定向放射外科或大分割立体定向放疗的105例连续患者,共111个脑干转移瘤,每例1-2个转移灶,组织学来源多样。
  • 评估指标包括无局部进展生存、癌症特异性生存、总生存及治疗相关毒性,并分析治疗反应和生存的预测因素。

主要发现

  • 中位随访时间10个月(范围3-130个月),1年无局部进展率为90.4%。
  • 单因素分析中肿瘤体积≤0.4 cc和同步靶向治疗与更长无局部进展相关,联合治疗仍为显著独立预测因素[0.058,HR 0.139(95%CI 0.0182-1.064)]。
  • 中位总生存为11个月,中位癌症特异性生存为14.6个月。
  • 多因素分析中同步靶向治疗与更长总生存显著相关[HR 0.514(95%CI 0.302-0.875);p=0.01]。
  • 神经系统死亡发生于30.4%的患者,但仅3例(2.8%)归因于局部进展。

临床怎么用

  • 原文结论认为基于直线加速器的立体定向放射外科/大分割立体定向放疗为脑干转移瘤提供了良好的局部控制,治疗相关毒性低,且对总生存无 apparent 不利影响。
  • 原文结论指出以消融意图治疗时脑干转移瘤是神经系统死亡的少见原因。
  • 作者认为脑干转移瘤患者不应被先验地排除在临床试验之外。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Brainstem metastases (BSM) are associated with a poor prognosis and their management represents a therapeutic challenge. BSM are often inoperable and, in absence of randomized trials, the optimal radiation treatment of BSM remains to be defined. We evaluated the efficacy and toxicity of linear accelerator (linac)-based stereotactic radiosurgery (SRS) and hypofractionated steretotactic radiotherapy (HSRT) in the treatment of BSM in a series of patients treated in different clinical centers. METHODS: We conducted a multicentric retrospective study of patients affected by 1-2 BSM from different histologies who underwent SRS/HSRT. Freedom from local progression (FLP), cancer-specific survival (CSS), overall survival (OS), and treatment-related toxicity were evaluated. In addition, predictors of treatment response and survivals were evaluated. RESULTS: Between 2008 and 2021, 105 consecutive patients with 111 BMS who received SRS or HSRT for 1-2 BSM were evaluated. Median follow-up time was 10 months (range 3-130). One-year FLP rate was 90.4%. At the univariate analysis, tumor volume ≤ 0.4 cc, and concurrent targeted therapy were associated with longer FLP, with combined treatment that remained a significant independent predictor [0.058, HR 0.139 (95% CI 0.0182-1.064]. Median OS and CSS were 11 months and 14.6 months, respectively. At multivariate analysis, concurrent targeted therapy administration was significantly associated with longer OS [HR 0.514 (95%CI 0.302-0.875); p = 0.01]. Neurological death occurred in 30.4% of patients, although this was due to local progression in only 3 (2.8%) patients. CONCLUSION: Linac-based SRS/HSRT offers excellent local control to patients with BSM, with low treatment-related toxicity and no apparent detrimental effects on OS. When treated with ablative intent, BSM are an uncommon cause of neurological death. The present results indicates that patients with BSM should not be excluded a priori from clinical trials.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Nicosia L, Navarria P, Pinzi V, et al. Stereotactic radiosurgery for the treatment of brainstem metastases: a multicenter retrospective study. Radiat Oncol. 2022. PMID: 35945597. doi:10.1186/s13014-022-02111-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。